CP-316819

CP 316819 is a potent glycogen phosphorylase (GPase) inhibitor with antihyperglycemic effect (IC50 values are 17 and 34 nM against human skeletal muscle glycogen phosphorylase (huSMGPa) and liver glycogen phosphorylase (huLGPa) respectively) .CP 316819 causes glycogen accumulation under normoglycemic conditions but permits glycogen utilization when glucose concentrations are low.CP-316819 prevents neuronal cell death and maintains brain electrical currents[1][2].

Product Specifications

CAS Number

[186392-43-8]

Product Name Alternative

GPi 819

UNSPSC

12352005

Hazard Statement

H301

Target

Phosphorylase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/cp-316819.html

Purity

99.0

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

CON(C)C([C@H](O)[C@H](CC1=CC=CC=C1)NC(C2=CC3=CC(Cl)=CC=C3N2)=O)=O

Molecular Formula

C21H22ClN3O4

Molecular Weight

415.87

Precautions

H301

References & Citations

[1]Baker DJ, Timmons JA, Greenhaff PL. Glycogen phosphorylase inhibition in type 2 diabetes therapy: a systematic evaluation of metabolic and functional effects in rat skeletal muscle. Diabetes. 2005 Aug;54 (8) :2453-9. |[2]Suh SW, Bergher JP, Anderson CM, Treadway JL, Fosgerau K, Swanson RA. Astrocyte glycogen sustains neuronal activity during hypoglycemia: studies with the glycogen phosphorylase inhibitor CP-316,819 ([R-R*, S*]-5-chloro-N-[2-hydroxy-3- (methoxymethylamino) -3